Clinical trials
Pulmonary clinical trials
Below are recruiting pulmonary clinical trials, each written for real people, not researchers. We’re tracking 1,310 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07253883Recruiting
New breathing device test for asthma and COPD
This trial is testing a new breathing device that may be as accurate as standard tests for diagnosing asthma and COPD. It could offer a simpler and quicker way to check your lung health.
Liverpool, MerseysideAges 18–110 - NCT07869147RecruitingPhase 2
Study of ORJ-001 for idiopathic pulmonary fibrosis
This trial tests a new medicine, ORJ-001, for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help slow the disease and improve breathing.
Doral, FloridaAges 40 years+ - NCT06889467Recruiting
Testing leftover fluid from lymph node biopsies to find lung cancer
This trial is for people who are scheduled for a lung cancer biopsy (EBUS-TBNA) because doctors suspect non-small cell lung cancer (NSCLC) has spread to lymph nodes. It will test leftover fluid from the biopsy to see if it improves cancer detection. If your biopsy is negative but you still need surgery to remove lymph nodes, you can help us learn more about this new test.
AshkelonAges 18 years+ - NCT07194382RecruitingPhase 2
Testing a new liquid form of nintedanib for IPF
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
Camperdown, New South WalesAges 40 years+ - NCT03351842RecruitingPhase 2
Surgery alone or plus chemotherapy for early lung cancer
This trial studies whether adding chemotherapy after surgery helps people with early-stage lung adenocarcinoma that has a micropapillary pattern. It’s testing whether chemotherapy given after complete tumor removal can improve outcomes compared with surgery alone.
ShanghaiAges 19–70 - NCT04095351Recruiting
Study of connective tissue disease affecting the lungs
This study looks at people aged 18 and older who have a connective tissue disease and lung involvement. It aims to better understand how these lung problems progress and may help doctors choose better care.
InnsbruckAges 18–80 - NCT03331302RecruitingPhase 1/Phase 2
Tested lung imaging scans in stable COPD patients
This study compares two ways of seeing how well your lungs work: a special MRI scan and another scan that uses a different gas. It may help researchers find which imaging test best reflects lung function in people with COPD.
Charlottesville, VirginiaAges 18 years+ - NCT04973579Recruiting
Stent plus heart surgery for high risk carotid patients
This trial looks at whether doing carotid artery stenting at the same time as heart surgery is safe and effective for people at high risk of stroke around the time of surgery. It targets people with significant carotid narrowing who also need heart surgery for specific heart problems.
KrakowAges 18 years+ - NCT04822077Recruiting
Proton beam treatment for thymus tumors
This trial studies proton radiotherapy (a type of radiation) for cancers of the thymus, like thymoma or thymic carcinoma. It may help improve tumor control while limiting radiation exposure to nearby organs.
Umeå, NorrlandAges 18 years+ - NCT04879069Recruiting
Registry study for recent high-risk blood clot in the lungs
This trial is a registry that collects information about people with a recent lung blood clot diagnosed by CT scan. It particularly focuses on higher-risk cases to better understand outcomes and care in the first 2 weeks after symptoms start.
Poznan, GreaterPolandAges 18 years+ - NCT04200079Recruiting
Long-term follow-up study for people with COPD
This study follows people with COPD over time to better understand their lung health and how it changes. It may help researchers and doctors learn what factors affect breathing and long-term outcomes.
Kingston, OntarioAges 40–85 - NCT05053802RecruitingPhase 2
Microwave tumor ablation plus immunotherapy for multiple lung cancers
This Phase 2 trial studies whether combining microwave ablation (a procedure to destroy lung tumors) with an immune checkpoint inhibitor can control multiple early lung cancers safely. It also aims to see how well the immune treatment helps after ablation, in people whose cancers have not spread.
Shanghai, Shanghai MunicipalityAges 18–79 - NCT03193892Recruiting
National registry for women with lymphangioleiomyomatosis
This trial is a national health registry that collects medical information from women with lymphangioleiomyomatosis (LAM), a rare lung condition. It helps researchers better understand who has LAM and what their health looks like over time.
Beijing, Beijing MunicipalityAges Any age - NCT05221372Recruiting
Sampling study for lung cancer patients on targeted pills
This trial collects blood samples from adults with advanced lung cancer that has a specific gene change and who are already taking targeted pill treatment (TKIs). The goal is to learn from these samples and how they relate to the cancer in patients on standard therapy.
RotterdamAges 18 years+ - NCT02803242Recruiting
Patient research network for people with lung symptoms
This trial enrolls adults to help build a patient-powered research network for chronic lung disease. If you join, you’ll likely be asked to complete surveys or provide information to help researchers learn how symptoms and health outcomes change over time.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05289245Recruiting
Registry study for Chinese people with cystic fibrosis
This study keeps a national record of people diagnosed with cystic fibrosis (CF) in China. It aims to better understand CF over time and may help future care by improving how patients are tracked and studied.
Beijing, Beijing MunicipalityAges Any age - NCT04684602RecruitingPhase 1/Phase 2
Study of stem cells for several short- and long-term illnesses
This early-stage study tests whether injections of mesenchymal stem cells can be safe and helpful for certain chronic (long-term) and acute (short-term) conditions. You might be considered if you can consent, are able to return for follow-up visits, and do not have key reasons that would make stem-cell treatment unsafe.
Culver City, CaliforniaAges 18 years+ - NCT05375591Recruiting
AI study to sort lung nodules after past cancer treatment
This study uses computer tools (AI) and detailed scan patterns to better classify new lung nodules in people who previously had curative-intent cancer treatment. It may help doctors decide whether a nodule is likely benign or cancer, using your CT scan and related medical history.
LondonAges 18 years+ - NCT02755974Recruiting
Study of COPD flare-ups in adults with reduced lung function
This study follows people with COPD flare-ups (sudden worsening of breathing) to better understand what happens and what might help. You may be asked for consent and lung-function tests if you meet the breathing and age requirements.
LondonAges 40–100 - NCT05426720Recruiting
Looking for TB lung damage risk factors and blood markers
This study looks at what increases the risk of long-term lung damage after active pulmonary tuberculosis (TB). It also tests whether certain blood or other markers can predict who is more likely to have lung problems later.
BeijingAges 25–60 - NCT05490901Recruiting
Test exercise heart pressure measurements with an ultrasound
This study looks at how well two heart tests taken during exercise—direct heart pressure measurement and an ultrasound—can explain shortness of breath with activity. It may help doctors better diagnose what’s causing your symptoms.
SeoulAges 19 years+ - NCT05493267RecruitingPhase 4
Tested immune-cell therapy for drug-resistant tuberculosis
This trial studies an immune-based treatment made from certain T cells (Vγ2Vδ2 T lymphocytes) for multi-drug–resistant tuberculosis (MDR-TB). It may help people whose current drug regimen is not working well or who have limited effective options.
ShanghaiAges 18–65 - NCT05503667RecruitingPhase 2
Testing EGFR drugs before lung surgery in certain stage III cancers
This trial tests whether taking furmonertinib alone, or furmonertinib plus bevacizumab, before surgery can improve outcomes for people with EGFR-mutated lung adenocarcinoma that has not spread to distant organs. It may help shrink the tumor and make surgery more effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04018729RecruitingPhase 2/Phase 3
Cell treatment through a breathing tube for severe emphysema
This trial tests a cell-based treatment placed into the lung using an airway valve, to help people with severe emphysema breathe easier. You may be eligible if your emphysema is uneven in the lungs and testing suggests your “collateral ventilation” is low, meaning the treatment area may benefit more from blocking airflow.
Porto Alegre, Rio Grande do SulAges 18 years+
Hear when a new Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary?
- Yes. Clin2 currently lists 1,310 recruiting pulmonary studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.